Sodium-glucose cotransporter 2 inhibitor
Sodium-glucose cotransporter 2 inhibitor is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
1
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
Clinical Trials (4)
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4